A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...
MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide ...
A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...
“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...
Live Science on MSN10d
In a 1st, trial finds vitamin D supplements may slow multiple sclerosis. But questions remain.A new clinical trial has shown for the first time that taking high doses of vitamin D could stave off the progression of ...
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...
MedPage Today on MSN9d
Deciding Whether Multiple Sclerosis Treatment Should Be DiscontinuedObservational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...
Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative ...
March is regonized as multiple sclerosis awareness month. One woman is shining a light on MS and sharing a message of hope ...
Lohud.com, Westchester County on MSN5d
Teacher, 'multiple sclerosis champion' to be honoree at MS fundraiser in WestchesterIt took a decade for Heather Castellani Milboer to be diagnosed with multiple sclerosis. Now, she helps build community for ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback